Ultrahuman launches M2 Live metabolic health platform in US

Ultrahuman has launched its second-generation metabolic health platform, M2 Live, in the United States. The platform, which debuted on June 18, 2026, integrates glucose data from Abbott's over-the-counter Lingo continuous glucose monitor (CGM) with a suite of health metrics to provide users with personalized metabolic insights.

The launch positions M2 Live as one of the first consumer platforms to support Lingo, a prescription-free CGM designed for adults aged 18 and older who are not using insulin. By leveraging this sensor, Ultrahuman aims to lower the cost and complexity that have traditionally limited access to continuous glucose monitoring for wellness purposes. A single Lingo biosensor is priced at $129 and is designed to last up to 14 days. A monthly subscription plan, starting at $99, will also be available. The platform will go on sale via the company's website in the coming weeks.

A key differentiator for M2 Live is its contextual analysis of biological signals. While it can function independently, pairing the platform with the Ultrahuman Ring wearable and the company's Blood Vision biomarker service allows it to synthesize live glucose data with a broader array of...